Masatomo Miura

Akita, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 158 publications

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

Journal: British journal of haematology

Published: March 12, 2026

Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non-Small Cell Lung Cancer.

Drug Interaction Between Erlotinib and Itraconazole in a Patient With Non-Small Cell Lung Cancer.

Journal: Case reports in oncological medicine

Published: January 13, 2026

Influence of pharmacokinetics-related polymorphisms on asciminib exposure in patients with Japanese chronic myeloid leukemia.

Influence of pharmacokinetics-related polymorphisms on asciminib exposure in patients with Japanese chronic myeloid leukemia.

Journal: European journal of clinical pharmacology

Published: September 09, 2025

Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia.

Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia.

Journal: International journal of hematology

Published: December 14, 2024

Effects of CYP3A5 polymorphism and renal impairment on the drug interaction between venetoclax and fluconazole in acute myeloid leukaemia patients.

Effects of CYP3A5 polymorphism and renal impairment on the drug interaction between venetoclax and fluconazole in acute myeloid leukaemia patients.

Journal: Xenobiotica; the fate of foreign compounds in biological systems

Published: December 13, 2024

Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer.

Influence of interleukin-6 on the pharmacokinetics and pharmacodynamics of osimertinib in patients with non-small cell lung cancer.

Journal: Cancer chemotherapy and pharmacology

Published: November 28, 2024

Development and Validation of a Novel High-Performance Liquid Chromatography Assay with Ultraviolet Detection for Determination of Asciminib in Human Plasma.

Development and Validation of a Novel High-Performance Liquid Chromatography Assay with Ultraviolet Detection for Determination of Asciminib in Human Plasma.

Journal: Journal of chromatographic science

Published: November 27, 2024

Effects of the Japanese Kampo Medicines Rikkunshito, Shakuyakukanzoto and Goreisan on Lenvatinib Plasma Concentrations in Japanese Patients with Thyroid Cancer.

Effects of the Japanese Kampo Medicines Rikkunshito, Shakuyakukanzoto and Goreisan on Lenvatinib Plasma Concentrations in Japanese Patients with Thyroid Cancer.

Journal: Drugs - real world outcomes

Published: November 10, 2024

Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models.

Diarylpentanoid, a curcumin analog, inhibits malignant meningioma growth in both in vitro and in vivo models.

Journal: World journal of experimental medicine

Published: November 01, 2024

Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer.

Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer.

Journal: Cancer chemotherapy and pharmacology

Published: July 05, 2024

Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis.

Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis.

Journal: International journal of hematology

Published: May 30, 2024

A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).

A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).

Journal: International journal of hematology

Published: April 20, 2024

Showing 1-12 of 158

Last Updated: 09/26/2026